MNKD vs. IRWD, INVA, DVAX, LGND, OPK, PAHC, ANAB, RDUS, LXRX, and VSTM
Should you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), OPKO Health (OPK), Phibro Animal Health (PAHC), AnaptysBio (ANAB), Radius Recycling (RDUS), Lexicon Pharmaceuticals (LXRX), and Verastem (VSTM).
Ironwood Pharmaceuticals (NASDAQ:IRWD) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment.
49.6% of MannKind shares are owned by institutional investors. 13.1% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Ironwood Pharmaceuticals presently has a consensus price target of $18.40, indicating a potential upside of 183.95%. MannKind has a consensus price target of $8.00, indicating a potential upside of 74.29%. Given MannKind's higher possible upside, equities research analysts clearly believe Ironwood Pharmaceuticals is more favorable than MannKind.
MannKind has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.
MannKind received 69 more outperform votes than Ironwood Pharmaceuticals when rated by MarketBeat users. However, 61.09% of users gave Ironwood Pharmaceuticals an outperform vote while only 59.87% of users gave MannKind an outperform vote.
Ironwood Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.
In the previous week, MannKind had 2 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 13 mentions for MannKind and 11 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.42 beat MannKind's score of 0.11 indicating that MannKind is being referred to more favorably in the news media.
MannKind has a net margin of 3.78% compared to MannKind's net margin of -254.41%. Ironwood Pharmaceuticals' return on equity of -3.35% beat MannKind's return on equity.
Summary
MannKind beats Ironwood Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get MannKind News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MannKind Competitors List
Related Companies and Tools
